WallStSmart

Merck & Company Inc (MRK)vsTivic Health Systems Inc (TIVC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 13487659% more annual revenue ($65.01B vs $482,000). MRK leads profitability with a 28.1% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 59/100 (C).

MRK

Buy

59

out of 100

Grade: C

Growth: 4.0Profit: 9.5Value: 4.7Quality: 4.8
Piotroski: 3/9

TIVC

Hold

37

out of 100

Grade: F

Growth: 4.7Profit: 3.0Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKOvervalued (-13.2%)

Margin of Safety

-13.2%

Fair Value

$96.48

Current Price

$109.18

$12.70 premium

UndervaluedFair: $96.48Overvalued
TIVCOvervalued (-14.2%)

Margin of Safety

-14.2%

Fair Value

$0.76

Current Price

$0.96

$0.20 premium

UndervaluedFair: $0.76Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK6 strengths · Avg: 9.2/10
Market CapQuality
$274.03B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
32.8%10/10

Strong operational efficiency at 32.8%

Profit MarginProfitability
28.1%9/10

Keeps 28 of every $100 in revenue as profit

P/E RatioValuation
15.2x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

TIVC2 strengths · Avg: 9.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Areas to Watch

MRK3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.362/10

Expensive relative to growth rate

EPS GrowthGrowth
-19.3%2/10

Earnings declined 19.3%

TIVC4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$3.83M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.

Bull Case : TIVC

The strongest argument for TIVC centers on Price/Book, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.

Bear Case : TIVC

The primary concerns for TIVC are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

MRK profiles as a value stock while TIVC is a growth play — different risk/reward profiles.

TIVC carries more volatility with a beta of 1.84 — expect wider price swings.

TIVC is growing revenue faster at 15.9% — sustainability is the question.

MRK generates stronger free cash flow (1.8B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (59/100 vs 37/100), backed by strong 28.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Tivic Health Systems Inc

HEALTHCARE · MEDICAL DEVICES · USA

Tivic Health Systems Inc (TIVC) is a pioneering medical technology firm focused on developing non-invasive bioelectronic therapies aimed at addressing chronic conditions, particularly allergic rhinitis. Leveraging its proprietary platform and extensive clinical expertise, Tivic Health is committed to delivering innovative solutions that not only meet critical patient needs but also optimize healthcare delivery. Positioned at the vanguard of the burgeoning bioelectronic medicine landscape, the company is set to seize emerging market opportunities, significantly improving patient outcomes and establishing new benchmarks in chronic condition management.

Want to dig deeper into these stocks?